The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia

Journal of Clinical Lipidology

Volumn 7, Issue 5, 2013, Pages 446-453

  Ghani, Rohana Abdul ^a   Yaakob, Ismail Bin ^b   Wahab, Norasyikin Abdul ^a   Zainudin, Suehazlyn ^a   Mustafa, Norlaila ^a   Sukor, Norlela ^a   Wan Mohamud, Wan Nazaimoon ^c   Kadir, Khalid Abdul ^d   Kamaruddin, Nor Azmi ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b NATIONAL HEART INSTITUTE   (Malaysia)

^c INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^d MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Endothelial dysfunction; Fenofibrate; High density lipoprotein cholesterol; hsCRP; Low density lipoprotein; Noninvasive endothelial function assessments; Triglyceride; Vascular cell adhesion molecule 1

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC HYPERTENSION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ENDOTHELIAL DYSFUNCTION; FENOFIBRATE; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HSCRP; LOW DENSITY LIPOPROTEIN; NONINVASIVE ENDOTHELIAL FUNCTION ASSESSMENTS; TRIGLYCERIDE; VASCULAR CELL ADHESION MOLECULE-1;

ADULT; AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ENDOTHELIUM; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED;

EID: 84885019610     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.04.004     Document Type: Article

References (35)

1. S.H. Han, M.J. Quon, and K.K. Koh Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction Curr Opin Lipidol 18 2007 58 65
2. B. Guerci, A. Kearney-Schwartz, P. Böhme, F. Zannad, and P. Drouin Endothelial dysfunction and type 2 diabetes Diabetes Metab 27 2001 425 434
3. F.H. de Man, A.W. Weverling-Rijnsburger, A. van der Laarse, A.H. Smelt, J.W. Jukema, and G.J. Blauw Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvasatatin Atherioscler Thromb Vasc Biol 20 2000 744 750
4. American Diabetes Association (ADA) Dylipidaemia management in adults with diabetes Diabetes Care 27 2004 S68 S71
5. A.D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic hyper-apoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus Ann Intern Med 135 2001 447 459
6. G. O'Driscoll, D. Green, and R.R. Taylor Simvastatin, an HMG-Coenzyme A reductase Inhibitor, improves endothelial function within 1 month Circulation 95 1997 1126 1131
7. F.V. Venrooij, M.A. van dee Ree, and B.L. Mithcel Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: The diabetes atovarstatin lipid intervention (DALI) study: a randomized, double-blind, placebo-controlled trial Diabetes Care 25 2002 1211 1216
8. M. Evans, R.A. Anderson, J. Graham, G.R. Ellis, K. Morris, and S. Davies Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus Circulation 101 2000 1773 1779
9. J. Malik, V. Melenovsky, D. Wichterle, T. Haas, J. Simek, and R. Ceska Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (Fenofibrate versus Atorvastatin Trial: FAT) Cardiovasc Res 52 2001 290 298
10. Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study (DAIS) Lancet 357 2001 905 910
11. K.K. Koh, S.H. Han, M.J. Quon, J. Yeal Ahn, and E.K. Shin Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hyper TG Diabetes Care 28 2005 1419 1421
12. G.S. Hotamisligil The role of TNF-α and TNF-α receptors in obesity and insulin resistance J Intern Med 245 1999 621 626
13. N. Marx, G.K. Sukhova, T. Collins, P. Libby, and J. Plutzky PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 19 1999 3125 3131
14. M.J. Mullen, D. Wright, A.E. Donald, S. Thorne, H. Thomson, and J.E. Deanfield Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study J Am Coll Cardiol 36 2000 410 416
15. M. Elisaf Effects of fibrates on serum metabolic parameters Curr Med Res Opin 18 2002 269 276
16. R. Belfort, R. Berria, J. Cornell, and K. Cusi Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome J Clin Endocrinol Metab 95 2010 829 836
17. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
18. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 2 2002 257 265
19. D.S. Celermajer Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 30 1997 325 333
20. K.E. Sorensen, D.S. Celermajer, and D.J. Spiegelhalter Non-invasive measurement of endothelium-dependent arterial responses in man: accuracy and reproducibility Br Heart J 74 1995 247 253
21. P. Lundman, M.J. Eriksson, M. Stühlinger, J.P. Cooke, A. Hamsten, and P. Tornvall Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine J Am Coll Cardiol 38 2001 111 116
22. H. Gaenzer, G. Neumayr, P. Marschang, W. Sturm, M. Lechleitner, and B. Föger Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus Am J Cardiol 89 2002 431 434
23. D.A. Playford, G.F. Watts, J.D. Best, and V. Burke Effect of fenofibrate on brachial artery flow mediated dilation in Type 2 diabetes mellitus Am J Cardiol 90 2002 1254 1257
24. B. Idzior-Walus, J. Sieradzki, W. Rostworowski, A. Zdzienicka, E. Kawalec, and J. Wójcik Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X Eur J Clin Invest 30 2000 871 878
25. G.F. Watts, S. Herrmann, G.K. Dogra, D.A. Playford, J.D. Best, and M.A. Thomas Vascular function of the peripheral circulation in patients with nephrosis Kidney Int 60 2001 182 189
26. C. Seiler, T.M. Suter, and O.M. Hess Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after lipid lowering drugs therapy with bezafibrates J Am Coll Cardiol 26 1995 1615 1622
27. J.T. Kuvin, M.E. Rämet, A.R. Patel, N.G. Pandian, M.E. Mendelsohn, and R.H. Karas A novel mechanism for the beneficial vascular effects of high-density cholesterol enhanced vaso relaxation and increased endothelial nitric oxide synthase expression Am Heart J 144 2002 165 172
28. R.J. Bisoendial, G.K. Hovingh, J.H. Levels, P.G. Lerch, I. Andresen, and M.R. Hayden Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein Circulation 107 2003 2944 2948
29. D.M. Capuzzi, and J.S. Freeman C-reactive protein and cardiovascular risk in metabolic syndrome and type 2 diabetes: controversy and challenge Clin Diabetes 25 2007 16 22
30. A. Jager, V.W. van Hinsbergh, P.J. Kostense, J.J. Emeis, J.S. Yudkin, and G. Nijpels Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study Arterioscler Thromb Vasc Biol 19 1999 3071 3078
31. R.S. Rosenson, and W. Koenig High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease Curr Opin Cardiol 17 2002 325 331
32. P. Fasching, M. Veitl, M. Rohac, C. Streli, B. Schneider, and W. Waldhäusl Elevated concentration of circulating adhesion molecule and their association with macrovascular complications in insulin dependent diabetes J Clin Endocrinol Metabol 81 1996 4313 4318
33. C.J. Lowenstein, and S.J. Cameron High-density lipoprotein metabolism and endothelial function Curr Opin Endocrinol Diabetes Obes 17 2010 166 170
34. H. Haller, D. Schaper, W. Ziegler, S. Philipp, M. Kuhlmann, and A. Distler Low-density lipoprotein induces vascular adhesion molecule expression on human endothelial cells Hypertension 25 1995 511 516
35. S.P. Zhao, and J. Wu Fenofibrate reduces TNF-α serum concentration and adipocyte secretion of hypercholesterolemic rabbits Clin Chim Acta 347 2004 145 150